87

Hematology&Oncology
Sub Categories on Hematology&Oncology
Latest Articles
Targeted therapy improves long-term outcomes for patients with rare mutations driving lung cancer

Targeted therapy improves long-term outcomes for patients with rare mutations driving lung cancer

byMass General BrighamCredit: Unsplash/CC0 Public DomainIn some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical stu

Targeted therapy improves long-term outcomes for patients with rare mutations driving lung cancer

byMass General BrighamCredit: Unsplash/CC0 Public DomainIn some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical stu
Unexpected findings on lung cancer CT scans may point to other non-lung cancers

Unexpected findings on lung cancer CT scans may point to other non-lung cancers

byBrown UniversityCredit: CC0 Public DomainWhen doctors review diagnostic medical scans for lung cancer, they sometimes spot abnormalities unrelated to the lungs. New research shows that some of those

Unexpected findings on lung cancer CT scans may point to other non-lung cancers

byBrown UniversityCredit: CC0 Public DomainWhen doctors review diagnostic medical scans for lung cancer, they sometimes spot abnormalities unrelated to the lungs. New research shows that some of those
TYK2 protein suppresses breast cancer metastasis by sensing extracellular stiffness, research finds

TYK2 protein suppresses breast cancer metastasis by sensing extracellular stiffness, research finds

by Miles Martin,University of California - San DiegoIn healthy tissues, seen in the top two panels here, TYK2 (green) is found on the cell membrane and colocalizes with E-cadherin (red), a protein tha

TYK2 protein suppresses breast cancer metastasis by sensing extracellular stiffness, research finds

by Miles Martin,University of California - San DiegoIn healthy tissues, seen in the top two panels here, TYK2 (green) is found on the cell membrane and colocalizes with E-cadherin (red), a protein tha
Shields and bodyguards: Scientists uncover the hidden defenses of a deadly childhood cancer

Shields and bodyguards: Scientists uncover the hidden defenses of a deadly childhood cancer

byUniversity of QueenslandNeuroblastoma imaging showing cancer cells (white), immune cells (yellow) supportive tissue (blue) and blood vessels (red). Credit: University of QueenslandResearchers have c

Shields and bodyguards: Scientists uncover the hidden defenses of a deadly childhood cancer

byUniversity of QueenslandNeuroblastoma imaging showing cancer cells (white), immune cells (yellow) supportive tissue (blue) and blood vessels (red). Credit: University of QueenslandResearchers have c
Heat-activated skin patch can kill melanoma cells without surgery

Heat-activated skin patch can kill melanoma cells without surgery

byAmerican Chemical SocietyThis bandage-like patch could someday be part of an effective and noninvasive treatment for melanoma. Credit:ACS Nano(2026). DOI: 10.1021/acsnano.5c21102Melanoma is a deadly

Heat-activated skin patch can kill melanoma cells without surgery

byAmerican Chemical SocietyThis bandage-like patch could someday be part of an effective and noninvasive treatment for melanoma. Credit:ACS Nano(2026). DOI: 10.1021/acsnano.5c21102Melanoma is a deadly
FDA-approved oral AML therapy could let older patients avoid monthly infusion visits

FDA-approved oral AML therapy could let older patients avoid monthly infusion visits

byWeill Cornell Medical CollegeCredit: Unsplash/CC0 Public DomainThe ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is a

FDA-approved oral AML therapy could let older patients avoid monthly infusion visits

byWeill Cornell Medical CollegeCredit: Unsplash/CC0 Public DomainThe ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is a
RAS(ON) inhibitor doubles median overall survival in patients with metastatic pancreatic cancer

RAS(ON) inhibitor doubles median overall survival in patients with metastatic pancreatic cancer

byDana-Farber Cancer InstituteAxial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domainA shift in the way people think about and treat pancreatic canc

RAS(ON) inhibitor doubles median overall survival in patients with metastatic pancreatic cancer

byDana-Farber Cancer InstituteAxial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domainA shift in the way people think about and treat pancreatic canc
Immunotherapy plus chemo cuts stage three dMMR colon cancer recurrence by 50%

Immunotherapy plus chemo cuts stage three dMMR colon cancer recurrence by 50%

byMayo ClinicCredit: Pixabay/CC0 Public DomainColon cancer is the third most prevalent form of cancer in the U.S., and its incidence is increasing among younger adults, particularly those younger than

Immunotherapy plus chemo cuts stage three dMMR colon cancer recurrence by 50%

byMayo ClinicCredit: Pixabay/CC0 Public DomainColon cancer is the third most prevalent form of cancer in the U.S., and its incidence is increasing among younger adults, particularly those younger than
Targeted screening blitz could bring Indigenous cervical cancer elimination to 2036

Targeted screening blitz could bring Indigenous cervical cancer elimination to 2036

byAustralian National UniversityPredicted cervical cancer incidence (age standardized, per 100,000 females) between 2020 and 2100. Credit:The Lancet Public Health(2026). DOI: 10.1016/s2468-2667(26)000

Targeted screening blitz could bring Indigenous cervical cancer elimination to 2036

byAustralian National UniversityPredicted cervical cancer incidence (age standardized, per 100,000 females) between 2020 and 2100. Credit:The Lancet Public Health(2026). DOI: 10.1016/s2468-2667(26)000
Common metabolic enzyme could predict cancer immunotherapy benefits—and help more patients respond

Common metabolic enzyme could predict cancer immunotherapy benefits—and help more patients respond

by Andrew Smith,Rutgers UniversityCredit:Cell Reports Medicine(2026). DOI: 10.1016/j.xcrm.2026.102704Immunotherapies have transformed cancer treatment by helping the immune system recognize and attack

Common metabolic enzyme could predict cancer immunotherapy benefits—and help more patients respond

by Andrew Smith,Rutgers UniversityCredit:Cell Reports Medicine(2026). DOI: 10.1016/j.xcrm.2026.102704Immunotherapies have transformed cancer treatment by helping the immune system recognize and attack
Breast cancer hijacks the lung repair system to fuel tumor growth, study finds

Breast cancer hijacks the lung repair system to fuel tumor growth, study finds

byUniversity of Colorado AnschutzResearchers at the CU Anschutz Cancer Center have discovered how breast cancer cells that spread to the lungs may take advantage of the body's natural healing resp

Breast cancer hijacks the lung repair system to fuel tumor growth, study finds

byUniversity of Colorado AnschutzResearchers at the CU Anschutz Cancer Center have discovered how breast cancer cells that spread to the lungs may take advantage of the body's natural healing resp
After allogeneic transplant, VIC-1911 regimen shows low severe GVHD and no relapse

After allogeneic transplant, VIC-1911 regimen shows low severe GVHD and no relapse

byRoswell Park Comprehensive Cancer CenterCredit: Unsplash/CC0 Public DomainResults of a Phase I clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a low

After allogeneic transplant, VIC-1911 regimen shows low severe GVHD and no relapse

byRoswell Park Comprehensive Cancer CenterCredit: Unsplash/CC0 Public DomainResults of a Phase I clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a low